NDA 019599 · Legacy
Naftin
Naftifine Hydrochloride · Topical
NovelLast checked: Nov 20, 2026Latest source record: Apr 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Feb 29, 1988
Approved uses
6
Original approval plus efficacy supplements
Registered trials
14
5 Phase 3, 0 recruiting
FAERS reports
334
161 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 10, 2016 Supplement 13 · Efficacy LabelLetterPediatric Medical Review
- Oct 10, 2014 Supplement 12 · Efficacy LabelLetter
- Jan 13, 2012 Supplement 11 · Efficacy ReviewLabelLetter
- Jul 5, 1990 Supplement 2 · Efficacy
- Apr 5, 1989 Supplement 1 · Efficacy
- Feb 29, 1988 Original approval · Type 1 - New Molecular Entity
2 products under this application
- NAFTIN · NAFTIFINE HYDROCHLORIDE 2% · CREAM, TOPICAL · Prescription · TE AB
- NAFTIN · NAFTIFINE HYDROCHLORIDE 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CREAM, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Naftifine" as an intervention, any sponsor and status, largest first.
- Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT02335255 · 1,519 participants · Start Jun 27, 2014 · Primary completion May 15, 2018
Drug: Naftifine Hydrochloride Gel 2%; Naftin® Gel 2% and 1 more · For: Tinea Pedis
- Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01580891 · 1,053 participants · Start May 2012 · Primary completion Mar 2013
Drug: Naftifine HCl Cream 1%; Naftin® (Naftifine HCl) Cream 1% and 1 more · For: Tinea Pedis
- Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT02132260 · 890 participants · Start Aug 2013 · Primary completion Feb 2014
Drug: Naftifine Hydrochloride Cream 2%; Naftin® (Naftifine Hydrochloride) Cream 2% and 1 more · For: Tinea Pedis
- Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea PedisPivotal-lookingCompleted
Merz North America, Inc.Industry
NCT01290341 · 860 participants · Start Feb 2011 · Primary completion Nov 2011
Drug: NAFT-600 (naftin 2 % gel); Placebo · For: Tinea Pedis
Sites: Tucson, Arizona; Encino, California; San Diego, California · 23 sites in all
- Efficacy and Safety of NAFT-600 in Subjects With Tinea PedisPivotal-lookingCompleted
Merz North America, Inc.Industry
NCT01289015 · 855 participants · Start Feb 2011 · Primary completion Nov 2011
Drug: NAFT-600 ( naftin 2 % gel ); Placebo · For: Tinea Pedis
Sites: Phoenix, Arizona; San Diego, California; San Francisco, California · 23 sites in all
- Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea PedisPivotal-lookingCompleted
Merz North America, Inc.Industry
NCT00750139 · 707 participants · Start Aug 2008 · Primary completion Aug 2009
Drug: NAFT-500; Placebo 2-weeks and 2 more · For: Tinea Pedis; Athlete's Foot
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 17 sites in all
- BE Study of Naftifine HCLPivotal-lookingCompleted
Genzum Life SciencesIndustry
NCT02633813 · 693 participants · Start Mar 2015 · Primary completion Nov 2015
Drug: Naftifine hydrochloride 2%; Placebo and 1 more · For: Tinea Pedis
Sites: Brandon, Florida; Miami, Florida; Miramar, Florida · 14 sites in all
- Pediatric Subjects With Tinea CorporisPivotal-lookingCompleted
Merz North America, Inc.Industry
NCT02227290 · 230 participants · Start Aug 2014 · Primary completion Nov 2015
Drug: Naftin Cream; Placebo Cream · For: Tinea Corporis
Sites: Tucson, Arizona; Encino, California; Fremont, California · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus33
- blister27
- skin exfoliation26
- hypersensitivity25
- chronic kidney disease24
- drug ineffective24
- rash23
- erythema21
- off label use20
- diarrhoea18
- pain18
- renal failure18
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 9 |
| 2012 | 14 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 34 |
| 2016 | 46 |
| 2017 | 24 |
| 2018 | 32 |
| 2019 | 33 |
| 2020 | 28 |
| 2021 | 23 |
| 2022 | 18 |
| 2023 | 13 |
| 2024 | 9 |
| 2025 | 10 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Naftin (Naftifine HCl)
2024 spending
$776K
Beneficiaries
625
1,409 claims
Per beneficiary
$1,241
$9.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,948,778 |
| 2021 | $2,237,312 |
| 2022 | $2,875,420 |
| 2023 | $2,362,346 |
| 2024 | $775,716 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Naftifine Hydrochloride Gel 2%: An Effective Topical Treatment for Moccasin-Type Tinea Pedis.
Stein Gold LF, Vlahovic T, Verma A, et al. · J Drugs Dermatol 2015 · Meta-Analysis, Multicenter Study
- Athlete's foot.
Crawford F · BMJ Clin Evid 2006 · Systematic Review
- A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis.
Abo Zeid M, Elrosasy A, Alkousheh H, et al. · Arch Dermatol Res 2025 · Systematic Review, Meta-Analysis
- Naftifine cream 1% compared with miconazole cream 2% in dermatophytosis.
el Darouti MA, Kalinka P · Int J Dermatol 1990 · Clinical Trial, Comparative Study
- Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections.
Nada M, Hanafi S, al-Omari H, et al. · Int J Dermatol 1994 · Clinical Trial, Comparative Study
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.